|
|
|
| First Name: | Philippe | | Last Name: | Marambaud | | Title: | Associate Investigator | | Advanced Degrees: | Ph.D. | | Affiliation: | The Feinstein Institute for Medical Research - North-Shore LIJ | | Department: | Litwin-Zucker Research Center | | Street Address 1: | 350 Community Drive | | City: | Manhasset | | State/Province: | NY | | Zip/Postal Code: | 11030 | Country/Territory: | U.S.A. | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports no financial or other potential conflicts of interest. [Last Modified: 21 September 2011]
|
|
|
View all comments by Philippe Marambaud
|
Tauopathies, Parkinson Disease, Aging Process, Alzheimer Disease, Prion Diseases, Polyglutamine Disorders (Huntington's, etc.)
|
Animal Models, Signal transduction, Neurobiology, Genetics, Molecular and Cell biology, A-beta PP/A-beta
|
1. Chapuis J, Vingtdeux V, Campagne F, Davies P, Marambaud P*. Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-beta precursor protein. Hum Mol Genet. 2011 May 15;20(10):2026-36. PMID: 21357679
2. Koppel J, Campagne F, Vingtdeux V, Dreses-Werringloer U, Ewers M, Rujescu D, Hampel H, Gordon ML, Christen E, Chapuis J, Greenwald BS, Davies P, Marambaud P*. CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease. Mol Med. 2011 May 24. In press. PMID: 21629967
3. Vingtdeux V, Davies P, Dickson DW, Marambaud P*. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol. 2011 Mar;121(3):337-49. PMID: 20957377
4. Vingtdeux V, Chandakkar P, Zhao H, d'Abramo C, Davies P, Marambaud P*. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J. 2011 Jan;25(1):219-31. PMID: 20852062
5. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P*. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010 Mar 19;285(12):9100-13.
6. Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P*. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 2008 Jun 27;133(7):1149-61.
7. Marambaud P*, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005, 280: 37377-82.
8. Marambaud P and Robakis NK. Genetic and Molecular Aspects of Alzheimer’s disease Shed Light on New Mechanisms of Transcriptional Regulation. Genes, Brain and Behavior 2005, 4, 134-146.
9. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, Robakis NK. A CBP-binding transcriptional repressor produced by the PS1/γ-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003, 114, 635-645 (Commentary by Rao and Finkbeiner, Cell 2003, 114: 533-535; and by Fortini M., Nature 2003, 425: 565-566).
10. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, Wisniewski T, Robakis NK. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002 Apr 15;21(8):1948-56.
|
|
|
Home
